

UAMS News Bureau

Office of Communications & Marketing
4301 West Markham # 890
Little Rock, AR 72205-7199

uamshealth.com/news



News Release
Oct. 3, 2019

Media Contacts:

Leslie W. Taylor, 501-686-8998
Wireless phone: 501-951-7260
leslie@uams.edu

Katrina Dupins, 501-686-8149
Wireless phone: 501-920-6977
katrina@uams.edu

**UAMS Breast Center Patients Eligible to Participate
In National Mammography Research Study**

LITTLE ROCK – If it’s time for your annual mammogram, you may qualify to take part in a national research study at the University of Arkansas for Medical Sciences (UAMS).

TMIST (Tomosynthesis Mammographic Imaging Screening Trial) compares two standard breast cancer screening methods: tomosynthesis (3D) mammograms and digital (2D) mammograms. The study is designed to help researchers determine whether one method is better than the other at finding life-threatening breast cancers.

To find out if you qualify, contact the UAMS TMIST study coordinator at (501) 400-3195 or TMISTstudy@uams.edu.

“By participating in this research study, you can help determine the most effective type of mammogram and how often women should receive screening,” said Gwendolyn Bryant-Smith, M.D., chief of breast imaging at UAMS.





Women ages 45 to 74 who plan to get a routine screening mammogram at the UAMS Breast Center are eligible for this trial. Participants are randomly assigned to get either a 3D or 2D mammogram every one or two years for the first five years of the study. Researchers will follow each woman’s breast cancer status for a total of eight years by reviewing medical records and possibly conducting phone interviews.

Researchers plan to enroll a total of 165,000 women in the study at about 100 clinics in the United States and Canada.

TMIST was developed by the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group and the National Cancer Institute, part of the National Institutes of Health. ECOG-ACRIN leads the trial.

Participants must not be pregnant, intend to get pregnant or be lactating; have a history of breast cancer; show signs of breast disease; have had a screening mammogram in the past 11 months; or have breast implants or enhancements.

UAMS is the state's only health sciences university, with colleges of Medicine, Nursing, Pharmacy, Health Professions and Public Health; a graduate school; hospital; a main campus in Little Rock; a Northwest Arkansas regional campus in Fayetteville; a statewide network of regional campuses; and seven institutes: the Winthrop P. Rockefeller Cancer Institute, Jackson T. Stephens Spine & Neurosciences Institute, Harvey & Bernice Jones Eye Institute, Psychiatric Research Institute, Donald W. Reynolds Institute on Aging, Translational Research Institute and Institute for Digital Health & Innovation. It is the only adult Level 1 trauma center in the state. *U.S. News & World Report* named UAMS Medical Center the state's Best Hospital; ranked its ear, nose and throat program among the top 50 nationwide; and named six areas as high performing — cancer, colon cancer surgery, heart failure, hip replacement, knee replacement and lung cancer surgery. UAMS has 2,727 students, 870 medical residents and five dental residents. It is the state's largest public employer with more than 10,000 employees, including 1,200 physicians who provide care to patients at UAMS, its regional campuses, Arkansas Children's Hospital, the VA Medical Center and Baptist Health. Visit www.uams.edu or www.uamshealth.com. Find us on [Facebook](#), [Twitter](#), [YouTube](#) or [Instagram](#).

Like us, we're social:    

###